Another 43 lots of blood pressure medication recalled

Legacy Pharmaceuticals recalled 43 lots of losartan March 15, becoming the latest drugmaker to recall the blood pressure medication due to the detection of a potentially carcinogenic impurity.

The recalls affect three lots of losartan manufactured by Torrent Pharmaceuticals and 40 lots of losartan manufactured by Camber Pharmaceuticals.

In both cases, trace amounts of N-Nitroso N-Methyl 4-aminobutyric acid were detected in the medication. NMBA is a known animal carcinogen, and may cause cancer in humans.

This is the second recall issued due to the presence of NMBA. On March 1, Hetero Labs in India issued a recall of 87 lots of the tablets.

While this is only the second recall linked to the presence of NMBA, there have been two other likely carcinogenic impurities — N-Nitrosodimethylamine and N-Nitrosodiethylamine — detected in generic blood pressure drugs irbesartan and valsartan. As a result, there have been hundreds of recalls of generic blood pressure medications.

Find more about the recall notices here.


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars